Abstract
Increasing life expectancy in developed countries is revealing advancing age as the major risk factor for poor health. Animal research has revealed that ageing itself is malleable. Genetic and pharmacological manipulation of the underlying molecular pathways can produce broad-spectrum improved health during ageing, in individual tissues and the whole organism. Similar genotypes and phenotypes are enriched in humans who survive to advanced ages. This project will build upon these discoveries to identify potential drug targets to maintain health in ageing humans, using the uniquely powerful human cohort data at UCL, together with state-of-the-art platform technologies, experimental analysis, bioinformatics and modelling.
References
- López-Otín, C., Blasco, M.A., Partridge, L., Serrano, M., & Kroemer, G. (2013). The hallmarks of aging. Cell. Jun 6;153(6):1194-217
- Riera, C.E. & Dillin, A. 2015. Can aging be ‘drugged? Nature Medicine 21, 1400- 1405
- Sofat, R., Hingorani, A.D., Smeeth, L., Humphries, S.E., Talmud, P.J., Cooper, J., Shah, T., Sandhu, M.S., Ricketts, S.L., Boekholdt, S.M., et al. (2010). Separating the Mechanism-Based and Off-Target Actions of Cholesteryl Ester Transfer Protein Inhibitors With CETP Gene Polymorphisms. Circulation 121, 52–62
- Würtz, P., Wang, Q., Soininen, P., Kangas, A.J., Fatemifar, G., Tynkkynen, T., Tiainen, M., Perola, M., Tillin, T., Hughes, A.D., et al. (2016). Metabolomic Profiling of Statin Use and Genetic Inhibition of HMG-CoA Reductase. J. Am. Coll. Cardiol. 67, 1200–1210
- Hingorani, A., and Humphries, S. (2005). Nature’s randomised trials. The Lancet 366, 1906–1908